❓ Problem

Nicotine did not go away. It changed packaging. Cigarettes collapsed, the patches and gum that were built to treat them went with them, and the cessation aisle in your local pharmacy is now a museum exhibit aimed at a customer who mostly no longer exists.

The replacement categories, meanwhile, went vertical. The global nicotine pouch market sold 34 billion pouches in 2025, up 660% from 2020, and PMI alone shipped roughly 794 million cans of Zyn globally that year. The US pouch market grew 40% in a single year. Sean Frank puts usage at around 10% of 21-year-old men, and it is still climbing.

Here is the part nobody has priced in. 42% of adult pouch users say they started using pouches to quit smoking in the first place. These are not new nicotine users. They are people who already made one quit attempt, took the off-ramp the industry offered them, and landed on a product with no exit of its own. They are two addictions deep and the ladder only goes one way.

And they do want out, particularly once kids arrive. The advice on every quit-Zyn forum is identical: the ladder method, reduce your strength by roughly 10% a week until you reach nothing. It works. It is also a logistics exercise the user is expected to run entirely alone, buying three or four tins at different strengths, tracking their own schedule, and making a fresh decision every single time they reach into a pocket. The 6mg is right there in the drawer. On a bad Tuesday, the 6mg wins.

The gap is not another pouch. It is that nobody sells the protocol.

✅ Solution

A DTC pouch brand where the product is the taper: a subscription that steps you from 9mg to zero over 16 weeks and removes the decision from the user entirely.

• One intake, one curve. A 60-second quiz captures current strength, cans per week, years of use and a target quit date, then generates a personal taper slope. Someone on 9mg at two cans a week gets a different curve to someone on 6mg at five. No "choose your plan" screen.
• Boxes sorted by day, not by strength. This is the whole product. Every existing taper fails at the same moment, which is the moment the user opens a drawer containing a stronger option. Ship pre-sequenced day packs and there is no stronger option in the house.
• The last two weeks are 0mg. The ritual survives the chemistry. Users keep the pocket-check, the pouch under the lip, the thing to do with their hands, and the nicotine quietly leaves without a final-day cliff.
• Slips re-ladder, they do not reset. A bad week pushes the curve out rather than zeroing progress. Streak-shaming is how quit apps lose customers, and relapse is the base case in this category rather than the exception.
• Graduation into a standing 0mg line. The oral fixation reliably outlives the dependency. The customer who finishes the taper is not a churned customer, they are a flavour subscriber with no regulatory burden attached.

Start with Zyn users specifically, because they are the largest, youngest and most online cohort, and because "how to quit Zyn" is already a query with volume. Then widen to vapes, where the same protocol logic applies to a harder hardware problem.

The clever bit is that the product is not the pouch. It is the sequence.

📊 Key Numbers

Market size

• TAM: the global smoking cessation and nicotine de-addiction products market is worth about $8.8bn in 2026, heading for $13bn by 2033. NRT products hold roughly 48% of that, and behavioural support plus digital therapeutics is the fastest-growing slice.